Jump to content

Quality Chemical Industries Limited

Coordinates: 00°18′18″N 32°38′24″E / 0.30500°N 32.64000°E / 0.30500; 32.64000
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 23:04, 10 April 2016 (Dating maintenance tags: {{Fact}}). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cipla Quality Chemical Industries Limited
Company typePrivate
IndustryPharmaceutical Industry
Founded2005
HeadquartersLuzira, Kampala, Uganda
Key people
Emmanuel Katongole
executive chairman
Nevin Bradford
executive director & chief executive officer
ServicesPharmaceuticals
Total assetsUS$120 million (2012)
Number of employees
350 (2012)
WebsiteHomepage

Cipla Quality Chemical Industries Limited (CQCI) is a pharmaceutical manufacturing company in Uganda.

According to a 2007 published report, it was the only company in Africa that manufactured triple-combination antiretroviral (ARV) drugs.[1] CQCI also manufactures the antimalarial drug Lumartem, containing artemisinin and lumefantrine,[2] and the hepatitis B generic medicines Texavir and Zentair.[3][4]

Location

CQCI's pharmaceutical manufacturing plant sits on 12 acres (4.9 ha) of land.[citation needed] It is in Luzira, a neighborhood in Nakawa Division in southeastern Kampala. The plant is approximately 9 kilometres (5.6 mi), by road, south-east of Kampala's central business district.[5] The coordinates of the plant are 0° 18' 18.00"N, 32° 38' 24.00"E (Latitude:0.3050N; 32.6400E).[6]

History

In 2004, Quality Chemicals Limited (QCL) convinced Indian drug maker Cipla to go into a joint venture with QCL and the government of Uganda to establish a pharmaceutical plant in Uganda. Ground was broken in 2005 and the factory was commissioned in 2007[7] with a capacity of 6 million pills per day.[citation needed]

In 2009, TLG Capital invested an undisclosed amount of money in the plant.[8] Later, Capitalworks Investment Partners, a private equity firm based in South Africa, also became a shareholder in the plant.[citation needed] In February 2010, the government of Uganda divested from the plant by selling its shares "at cost" to CQCI. The transaction was valued at approximately US$5 million.[citation needed]

In February 2011, the owners of the plant announced an US$80 million expansion to the production line to include increased production of antiretroviral and antimalarial medication.[9] In April 2012, British media reported that CQCI was in the process of expanding its manufacturing capacity fourfold. The plant had received approval of its processes and products from the World Health Organization. The products will be initially marketed in Burundi, the Democratic Republic of the Congo, Kenya, Rwanda, South Sudan, Tanzania, and Uganda.[10]

According to a 2012 published report, a second plant is being planned to be built next to the first plant, which would raise CQCI's manufacturing capacity to 18 million pills daily.[11]

Ownership of pharmaceutical plant

As of March 2015, the shareholding in the pharmaceutical plant was as depicted in the table below:[citation needed]

Shareholding In CQCI Pharmaceutical Factory
Rank Name of Owner Percentage Ownership
1 Meditab Holdings Limited 51.05
2 Quality Chemicals Limited 22.05
3 Capitalworks Investment Partners 14.40
4 TLG Capital 12.50
Total 100.00

Governance

The executive chairman of the board of directors of CQCI is Emmanuel Katongole, who was formerly the managing director of QCIL. He replaced Francis Kitaka, the first person in East Africa to train as a biochemist,[12][13]

The managing director of CQCI is Nevin Bradford.[14]

See also

References

  1. ^ Wendo, Charles (6 October 2007). "ARVs Production Starts Monday". New Vision. Retrieved 23 June 2014.
  2. ^ Key, Data (2011). "Quality Chemical Industries, Uganda". Pharmaceutical Technology. Retrieved 23 June 2014.
  3. ^ CiplaQCi (2015). "Timeline & Milestones". Ciplaqcil.co.ug. Retrieved 10 April 2016.
  4. ^ CiplaQCi (December 2015). "Komboa Newsletter" (PDF). Ciplaqcil.co.ug. p. 4. Retrieved 10 April 2016.
  5. ^ "Map Showing Central Kampala And Luzira With Route Marker". Globefeed.com. Retrieved 17 March 2015.
  6. ^ Google. "Location of CIPLAQCIL Pharmaceutical Factory At Google Maps". Google Maps. Retrieved 17 March 2015. {{cite web}}: |last= has generic name (help)
  7. ^ Elvis Basudde, and Robert Kasozi (31 October 2007). "Kitaka, The Brain Behind Africa's First ARVs Factory". New Vision. Retrieved 23 June 2014.
  8. ^ Investment International (9 September 2009). "Ugandan Project Attracts Investors". InvestmentInternational.com. Retrieved 23 June 2014.
  9. ^ Gardner, Ann Marie (4 February 2011). "Teach a Man to Make Drugs: Pharmaceutical Companies Invest In African Generic Drug Plant". Good Is Magazine. Retrieved 23 June 2014.
  10. ^ BBC (9 April 2012). "Making Drugs Into Profit In Uganda". BBC News. Retrieved 23 June 2014.
  11. ^ Baguma, Raymond (18 May 2012). "Quality Chemicals Giving Ugandans Fighting Chance". New Vision. Retrieved 23 June 2014.
  12. ^ Senyonyi, Taddewo (4 January 2014). "Francis X. Kitaka: The Unsung Hero of Uganda's Health And Agricultural Sectors". Kampala: The CEO Magazine. Retrieved 9 April 2016.
  13. ^ Monitor Reporter (18 October 2013). "Emmanuel Katongole: The Founder of Quality Chemicals". Daily Monitor. Kampala. Retrieved 17 March 2015.
  14. ^ CIPLACQIL (30 November 2013). "Board of Directors of CIPLAQCIL". Ciplaqcil.co.ug. Retrieved 17 March 2015.

00°18′18″N 32°38′24″E / 0.30500°N 32.64000°E / 0.30500; 32.64000